{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:26:13Z","timestamp":1768706773885,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006315","name":"reumanederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"horizon 2020","doi-asserted-by":"publisher","award":["714312"],"award-info":[{"award-number":["714312"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rheumatoid arthritis (RA) is a heterogeneous disease, as evidenced by the differences in long-term outcomes. This applies especially to anti-citrullinated protein antibodies (ACPA)-negative RA, where a proportion achieves sustained DMARD-free remission (SDFR; sustained absence of synovitis after DMARD cessation). Differentiation of RA patients who will achieve SDFR can guide personalized treatment\/tapering strategies. Although this subgroup remains scarcely discerned, previous research demonstrated that these RA patients are characterized by an early clinical response (DAS remission after 4 months) after DMARD start. We studied whether, in addition to this clinical response, a specific biomarker response can further distinguish the subgroup of RA patients most likely to achieve SDFR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In 266 RA patients, levels of 12 biomarkers (SAA\/CRP\/MMP-1\/MMP-3\/resistin\/leptin\/IL-6\/TNF-R1\/YKL-40\/EGF\/VEGF\/VCAM-1), in the first 2 years after diagnosis, were studied in relation to SDFR, stratified for ACPA status. Subsequently, biomarkers associated with SDFR development were combined with early DAS remission to study its additional value in defining subgroups. Since most biomarker levels are not routinely measured in clinical practice, we explored how this subgroup can be clinically recognized.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>ACPA-negative RA patients achieving SDFR were characterized by high baseline levels and stronger decline in MMP-1\/MMP-3\/SAA\/CRP after DMARD-start, respectively 1.30\u00d7\/1.44\u00d7\/2.12\u00d7\/2.24\u00d7 stronger. This effect was absent in ACPA-positive RA. In ACPA-negative RA, a strong biomarker decline is associated with early DAS remission. The combination of both declines (clinical, biomarker) was present in a subgroup of ACPA-negative RA patients achieving SDFR. This subgroup can be clinically recognized by the combination of high baseline CRP levels (\u2265 3 times ULN), and early DAS remission (DAS<jats:sub>4 months<\/jats:sub> &lt; 1.6). This latter was replicated in independent ACPA-negative RA patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>ACPA-negative RA patients with early DAS remission and a strong biomarker response (or baseline CRP levels \u2265 3\u00d7 ULN) are most likely to achieve SDFR later on. This could guide personalized decisions on DMARD tapering\/cessation in ACPA-negative RA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02671-z","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T06:02:41Z","timestamp":1641189761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7850-5063","authenticated-orcid":false,"given":"M.","family":"Verstappen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. W.","family":"van Steenbergen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. H. P.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. H. M.","family":"van der Helm-van Mil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"2671_CR1","doi-asserted-by":"publisher","first-page":"102400","DOI":"10.1016\/j.jaut.2019.102400","volume":"110","author":"HU Scherer","year":"2020","unstructured":"Scherer HU, H\u00e4upl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun. 2020;110:102400.","journal-title":"J Autoimmun"},{"issue":"9","key":"2671_CR2","doi-asserted-by":"publisher","first-page":"e1003296","DOI":"10.1371\/journal.pmed.1003296","volume":"17","author":"XME Matthijssen","year":"2020","unstructured":"Matthijssen XME, Niemantsverdriet E, Huizinga TWJ, et al. Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: a longitudinal cohort study in the Netherlands. PLoS Med. 2020;17(9):e1003296. https:\/\/doi.org\/10.1371\/journal.pmed.1003296.","journal-title":"PLoS Med"},{"issue":"2","key":"2671_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/ard.2006.068247","volume":"67","author":"SW Syversen","year":"2008","unstructured":"Syversen SW, Gaarder PI, Goll GL, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis. 2008;67(2):212\u20137. https:\/\/doi.org\/10.1136\/ard.2006.068247.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2671_CR4","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/rheumatology\/ker516","volume":"51","author":"D van der Woude","year":"2012","unstructured":"van der Woude D, Visser K, Klarenbeek NB, et al. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology. 2012;51(6):1120\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/ker516.","journal-title":"Rheumatology"},{"issue":"1","key":"2671_CR5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13075-020-02368-9","volume":"22","author":"M Verstappen","year":"2020","unstructured":"Verstappen M, Niemantsverdriet E, Matthijssen XME, et al. Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):276. https:\/\/doi.org\/10.1186\/s13075-020-02368-9 published Online First: 25 Nov 2020.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2671_CR6","doi-asserted-by":"publisher","first-page":"R180","DOI":"10.1186\/ar3505","volume":"13","author":"DP De Rooy","year":"2011","unstructured":"De Rooy DP, Willemze A, Mertens B, et al. Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes? Arthritis Res Ther. 2011;13(5):R180. https:\/\/doi.org\/10.1186\/ar3505 published Online First: 29 Oct 2011.","journal-title":"Arthritis Res Ther"},{"key":"2671_CR7","doi-asserted-by":"publisher","unstructured":"Burgers LE, Boeters DM, Reijnierse M, et al. Does the presence of magnetic resonance imaging-detected osteitis at diagnosis with rheumatoid arthritis lower the risk for achieving disease-modifying antirheumatic drug-free sustained remission: results of a longitudinal study. Arthritis Res Ther. 2018;20(1). https:\/\/doi.org\/10.1186\/s13075-018-1553-8.","DOI":"10.1186\/s13075-018-1553-8"},{"issue":"1","key":"2671_CR8","doi-asserted-by":"publisher","first-page":"e001220","DOI":"10.1136\/rmdopen-2020-001220","volume":"6","author":"M Verstappen","year":"2020","unstructured":"Verstappen M, van Mulligen E, de Jong PHP, et al. DMARD-free remission as novel treatment target in rheumatoid arthritis: a systematic literature review of achievability and sustainability. RMD Open. 2020;6(1):e001220. https:\/\/doi.org\/10.1136\/rmdopen-2020-001220.","journal-title":"RMD Open"},{"issue":"1","key":"2671_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13075-019-1902-2","volume":"21","author":"DM Boeters","year":"2019","unstructured":"Boeters DM, Burgers LE, Sasso EH, et al. ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. Arthritis Res Ther. 2019;21(1):121. https:\/\/doi.org\/10.1186\/s13075-019-1902-2 published Online First: 16 May 2019.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2671_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/rheumatology\/keq230","volume":"50","author":"DP de Rooy","year":"2011","unstructured":"de Rooy DP, van der Linden MP, Knevel R, et al. Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford). 2011;50(1):93\u2013100. https:\/\/doi.org\/10.1093\/rheumatology\/keq230 published Online First: 20 July 2010.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"2671_CR11","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/ard.49.11.916","volume":"49","author":"DM van der Heijde","year":"1990","unstructured":"van der Heijde DM, van \u2018t Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49(11):916\u201320. https:\/\/doi.org\/10.1136\/ard.49.11.916 published Online First: 01 Nov 1990.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2671_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324. https:\/\/doi.org\/10.1002\/art.1780310302 published Online First: 01 March 1988.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2671_CR13","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381. https:\/\/doi.org\/10.1002\/art.27584 published Online First: 28 Sept 2010.","journal-title":"Arthritis Rheum"},{"key":"2671_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jpba.2012.06.003","volume":"70","author":"PS Eastman","year":"2012","unstructured":"Eastman PS, Manning WC, Qureshi F, et al. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal. 2012;70:415\u201324. https:\/\/doi.org\/10.1016\/j.jpba.2012.06.003 published Online First: 04 July 2012.","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"2671_CR15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2671_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13075-020-02293-x","volume":"22","author":"MS Jurgens","year":"2020","unstructured":"Jurgens MS, Safy-Khan M, de Hair MJH, et al. The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial. Arthritis Res Ther. 2020;22(1):205. https:\/\/doi.org\/10.1186\/s13075-020-02293-x.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"2671_CR17","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.4049\/jimmunol.166.4.2801","volume":"166","author":"R Vallon","year":"2001","unstructured":"Vallon R, Freuler F, Desta-Tsedu N, et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol. 2001;166(4):2801\u20137. https:\/\/doi.org\/10.4049\/jimmunol.166.4.2801 published Online First: 13 Feb 2001.","journal-title":"J Immunol"},{"issue":"1","key":"2671_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.berh.2008.08.002","volume":"23","author":"AG Pratt","year":"2009","unstructured":"Pratt AG, Isaacs JD, Mattey DL. Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2009;23(1):37\u201348. https:\/\/doi.org\/10.1016\/j.berh.2008.08.002 published Online First: 24 Feb 2009.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"2671_CR19","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.20301","volume":"50","author":"R O\u2019Hara","year":"2004","unstructured":"O\u2019Hara R, Murphy EP, Whitehead AS, et al. Local expression of the serum amyloid A and formyl peptide receptor\u2013like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum. 2004;50(6):1788\u201399. https:\/\/doi.org\/10.1002\/art.20301.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2671_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/ar78","volume":"2","author":"R O\u2019Hara","year":"2000","unstructured":"O\u2019Hara R, Murphy EP, Whitehead AS, et al. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res. 2000;2(2):142\u20134. https:\/\/doi.org\/10.1186\/ar78 published Online First: 24 Feb 2000.","journal-title":"Arthritis Res"},{"issue":"7","key":"2671_CR21","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1136\/annrheumdis-2016-210887","volume":"76","author":"H Zeidler","year":"2017","unstructured":"Zeidler H. Drug-free sustained remission or spontaneous remission by natural history in rheumatoid arthritis? An unsolved question: comment on the article of Ajeganova et al. Ann Rheum Dis. 2017;76(7):e16. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210887.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02671-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02671-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02671-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T06:11:24Z","timestamp":1641190284000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02671-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2671"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02671-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"assertion":[{"value":"24 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u201cCommisie Medische Ethiek\u201d of the Leiden University Medical Centre (B19.008).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}